Axovant Sciences Ltd - Company & Market Research Reports

Axovant Sciences is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics for the treatment of dementia in the United States and Europe. Its best known product, intepirdine, is a selective 5-HT6 receptor antagonist. It is currently in Phase III clinical trial for the treatment of Alzheimer's disease and in Phase II clinical trial for treating dementia. The company was formerly known as Roivant Neurosciences. Founded in 2014, it is based in Hamilton, Bermuda.

Global Alzheimer s Drug Market: Trends, Opportunities and Forecasts (2015-2020) (By Type - Imaging, Therapeutics, Diagnostics, Biomarkers; By Age: <65 years, >65 years age; By Region; Global Dementia Market) - Product Thumbnail Image

Global Alzheimer s Drug Market: Trends, Opportunities and Forecasts (2015-2020) (By Type - Imaging, Therapeutics, Diagnostics, Biomarkers; By Age: <65 years, >65 years age; By Region; Global Dementia Market)

  • Report
  • 106 Pages
From
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets - Product Thumbnail Image

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

  • Report
  • 144 Pages
From
Global Alzheimer's Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2015 to 2022 - Product Thumbnail Image

Global Alzheimer's Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2015 to 2022

  • Report
From
Global Alzheimer's Therapeutics Market Analysis 2016 - Forecast to 2022 - Product Thumbnail Image

Global Alzheimer's Therapeutics Market Analysis 2016 - Forecast to 2022

  • Report
  • 138 Pages
From
Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • 204 Pages
From
Alzheimer's Disease - Pipeline Review, H2 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H2 2018

  • Drug Pipelines
  • 1333 Pages
From
Alzheimer's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1203 Pages
From
Dementia - Pipeline Review, H2 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H2 2018

  • Drug Pipelines
  • 302 Pages
From
Parkinson's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Parkinson's Disease - Pipeline Review, H1 2018

  • Drug Pipelines
  • 881 Pages
From
Dementia - Pipeline Review, H1 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H1 2018

  • Drug Pipelines
  • 260 Pages
From
Lewy body Dementia - Pipeline Review, H2 2016 - Product Thumbnail Image

Lewy body Dementia - Pipeline Review, H2 2016

  • Drug Pipelines
  • 48 Pages
From
Lewy body Dementia - Pipeline Review, H1 2016 - Product Thumbnail Image

Lewy body Dementia - Pipeline Review, H1 2016

  • Drug Pipelines
  • 40 Pages
From
Lewy body Dementia - Pipeline Review, H2 2015 - Product Thumbnail Image

Lewy body Dementia - Pipeline Review, H2 2015

  • Drug Pipelines
  • 46 Pages
From
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

  • Report
  • 376 Pages
From
Neurodegenerative Disorders Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

  • Report
  • 797 Pages
From
Reversible Anticholinesterases -Pipeline Insight, 2018 - Product Thumbnail Image

Reversible Anticholinesterases -Pipeline Insight, 2018

  • Drug Pipelines
  • 90 Pages
From
Rodman & Renshaw Global Investment Conference - Axovant Sciences Ltd., - Earnings Transcript - Product Thumbnail Image

Rodman & Renshaw Global Investment Conference - Axovant Sciences Ltd., - Earnings Transcript

  • Earnings Transcript
Robert W. Baird Healthcare Conference - Axovant Sciences Ltd., - Earnings Transcript - Product Thumbnail Image

Robert W. Baird Healthcare Conference - Axovant Sciences Ltd., - Earnings Transcript

  • Earnings Transcript
Business Update Call - Axovant Sciences Ltd., - Earnings Transcript - Product Thumbnail Image

Business Update Call - Axovant Sciences Ltd., - Earnings Transcript

  • Earnings Transcript
JMP Securities Life Sciences Conference - Axovant Sciences Ltd., - Earnings Transcript - Product Thumbnail Image

JMP Securities Life Sciences Conference - Axovant Sciences Ltd., - Earnings Transcript

  • Earnings Transcript
Loading Indicator
adroll